MedTrace Logo

Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)

NCT07099742 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 364

Last updated 2025-08-03

No results posted yet for this study

Summary

This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in obese adults with or without Type 2 Diabetes Mellitus (T2DM).

The study aims to determine whether treatment with Tirzepatide results in superior weight reduction outcomes compared to lifestyle-based approaches. Adult participants (≥18 years) with a body mass index (BMI) ≥25 kg/m² and no prior exposure to GLP-1 receptor agonists will be enrolled at the discretion of the treating physician. Eligible participants will receive either once-weekly Tirzepatide or participate in lifestyle intervention programs aligned with standard clinical care.

Conditions

Interventions

DRUG

Tirzepatide

Exposure

BEHAVIORAL

Life Style Modification

Referent group - Lifestyle interventions, exercise, and diet control

Sponsors & Collaborators

  • Dr. Md. Alimur Reza

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. Indrajit Prasad, MBBS, MD(Endo) · Dhaka Medical College Hospital, Dhaka

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2026-04-30
Completion
2026-07-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07099742 on ClinicalTrials.gov